Unlikely to cause harm — often a labeling or packaging issue.
Failed Dissolution Specifications; 9-monthstability timepoint
| Distributed by / for | Jubilant Cadista Pharmaceuticals, Inc. |
| NDC | 59746- |
| Full product label | BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD |
| Recalling firm | Jubilant Cadista Pharmaceuticals, Inc. |
| Distribution | Product was distributed to one customer who may have further distributed the product. |
| Quantity | a) 3,072 bottles; b) 2,688 bottles |
| Recall initiated | 2019-02-28 |
| Report date | 2019-03-13 |
| Recall completed | 2020-03-05 |
| Recall number | D-0519-2019 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Salisbury MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗